nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ALB—multiple sclerosis	0.146	1	CbGaD
Erlotinib—CYP1B1—Mitoxantrone—multiple sclerosis	0.0752	0.158	CbGbCtD
Erlotinib—ABCG2—Cladribine—multiple sclerosis	0.049	0.103	CbGbCtD
Erlotinib—CYP1B1—Dexamethasone—multiple sclerosis	0.039	0.082	CbGbCtD
Erlotinib—ABCG2—Mitoxantrone—multiple sclerosis	0.0357	0.0752	CbGbCtD
Erlotinib—CYP2D6—Fingolimod—multiple sclerosis	0.0258	0.0543	CbGbCtD
Erlotinib—ALB—Prednisone—multiple sclerosis	0.0205	0.043	CbGbCtD
Erlotinib—ABCG2—Dexamethasone—multiple sclerosis	0.0185	0.039	CbGbCtD
Erlotinib—ABCB1—Methylprednisolone—multiple sclerosis	0.0177	0.0372	CbGbCtD
Erlotinib—CYP1A1—Dexamethasone—multiple sclerosis	0.0171	0.036	CbGbCtD
Erlotinib—CYP3A4—Fingolimod—multiple sclerosis	0.0164	0.0346	CbGbCtD
Erlotinib—ABCG2—Methotrexate—multiple sclerosis	0.0149	0.0313	CbGbCtD
Erlotinib—ABCB1—Mitoxantrone—multiple sclerosis	0.0129	0.0271	CbGbCtD
Erlotinib—ABCB1—Betamethasone—multiple sclerosis	0.0115	0.0242	CbGbCtD
Erlotinib—ABCB1—Prednisolone—multiple sclerosis	0.0113	0.0238	CbGbCtD
Erlotinib—ABCB1—Prednisone—multiple sclerosis	0.0107	0.0225	CbGbCtD
Erlotinib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0106	0.0223	CbGbCtD
Erlotinib—CYP3A5—Dexamethasone—multiple sclerosis	0.0103	0.0216	CbGbCtD
Erlotinib—ALB—Methotrexate—multiple sclerosis	0.0103	0.0216	CbGbCtD
Erlotinib—CYP2C8—Dexamethasone—multiple sclerosis	0.00987	0.0208	CbGbCtD
Erlotinib—CYP3A4—Triamcinolone—multiple sclerosis	0.00802	0.0169	CbGbCtD
Erlotinib—CYP3A4—Mitoxantrone—multiple sclerosis	0.00772	0.0162	CbGbCtD
Erlotinib—CYP3A4—Betamethasone—multiple sclerosis	0.00688	0.0145	CbGbCtD
Erlotinib—CYP3A4—Prednisolone—multiple sclerosis	0.00679	0.0143	CbGbCtD
Erlotinib—ABCB1—Dexamethasone—multiple sclerosis	0.00668	0.0141	CbGbCtD
Erlotinib—CYP3A4—Prednisone—multiple sclerosis	0.00641	0.0135	CbGbCtD
Erlotinib—CYP2D6—Dexamethasone—multiple sclerosis	0.00629	0.0132	CbGbCtD
Erlotinib—ABCB1—Methotrexate—multiple sclerosis	0.00537	0.0113	CbGbCtD
Erlotinib—CYP3A4—Dexamethasone—multiple sclerosis	0.004	0.00842	CbGbCtD
Erlotinib—PIP4K2C—retina—multiple sclerosis	0.00147	0.0218	CbGeAlD
Erlotinib—ULK3—retina—multiple sclerosis	0.00141	0.0208	CbGeAlD
Erlotinib—MKNK1—retina—multiple sclerosis	0.00132	0.0196	CbGeAlD
Erlotinib—AURKC—nervous system—multiple sclerosis	0.00121	0.0179	CbGeAlD
Erlotinib—AURKC—central nervous system—multiple sclerosis	0.00117	0.0173	CbGeAlD
Erlotinib—JAK3—nervous system—multiple sclerosis	0.00112	0.0166	CbGeAlD
Erlotinib—EPHA6—nervous system—multiple sclerosis	0.00112	0.0166	CbGeAlD
Erlotinib—HIPK4—brain—multiple sclerosis	0.00108	0.0161	CbGeAlD
Erlotinib—EPHA6—central nervous system—multiple sclerosis	0.00108	0.016	CbGeAlD
Erlotinib—JAK3—central nervous system—multiple sclerosis	0.00108	0.016	CbGeAlD
Erlotinib—LTK—brain—multiple sclerosis	0.00107	0.0159	CbGeAlD
Erlotinib—PIP4K2C—medulla oblongata—multiple sclerosis	0.00106	0.0158	CbGeAlD
Erlotinib—JAK3—cerebellum—multiple sclerosis	0.00106	0.0156	CbGeAlD
Erlotinib—MAP3K19—nervous system—multiple sclerosis	0.00102	0.0151	CbGeAlD
Erlotinib—ULK3—medulla oblongata—multiple sclerosis	0.00102	0.0151	CbGeAlD
Erlotinib—MAP2K5—brainstem—multiple sclerosis	0.00101	0.0149	CbGeAlD
Erlotinib—MAP3K19—central nervous system—multiple sclerosis	0.000982	0.0145	CbGeAlD
Erlotinib—PIP4K2C—midbrain—multiple sclerosis	0.000972	0.0144	CbGeAlD
Erlotinib—TNK1—cerebellum—multiple sclerosis	0.000969	0.0144	CbGeAlD
Erlotinib—MKNK1—medulla oblongata—multiple sclerosis	0.000956	0.0142	CbGeAlD
Erlotinib—PIP4K2C—spinal cord—multiple sclerosis	0.000949	0.0141	CbGeAlD
Erlotinib—ULK3—midbrain—multiple sclerosis	0.000928	0.0138	CbGeAlD
Erlotinib—AURKC—brain—multiple sclerosis	0.000926	0.0137	CbGeAlD
Erlotinib—ULK3—spinal cord—multiple sclerosis	0.000906	0.0134	CbGeAlD
Erlotinib—SLK—medulla oblongata—multiple sclerosis	0.000905	0.0134	CbGeAlD
Erlotinib—MKNK1—midbrain—multiple sclerosis	0.000874	0.0129	CbGeAlD
Erlotinib—JAK3—brain—multiple sclerosis	0.000857	0.0127	CbGeAlD
Erlotinib—EPHA6—brain—multiple sclerosis	0.000857	0.0127	CbGeAlD
Erlotinib—MKNK1—spinal cord—multiple sclerosis	0.000852	0.0126	CbGeAlD
Erlotinib—FLT3—cerebellum—multiple sclerosis	0.000833	0.0123	CbGeAlD
Erlotinib—SLK—midbrain—multiple sclerosis	0.000827	0.0123	CbGeAlD
Erlotinib—SLK—spinal cord—multiple sclerosis	0.000807	0.012	CbGeAlD
Erlotinib—PIP4K2C—nervous system—multiple sclerosis	0.000799	0.0118	CbGeAlD
Erlotinib—ABL2—cerebellum—multiple sclerosis	0.000795	0.0118	CbGeAlD
Erlotinib—TNK1—brain—multiple sclerosis	0.000787	0.0117	CbGeAlD
Erlotinib—MAP3K19—brain—multiple sclerosis	0.000779	0.0115	CbGeAlD
Erlotinib—ABL1—brainstem—multiple sclerosis	0.000778	0.0115	CbGeAlD
Erlotinib—EGFR—cerebellum—multiple sclerosis	0.000776	0.0115	CbGeAlD
Erlotinib—PIP4K2C—central nervous system—multiple sclerosis	0.000769	0.0114	CbGeAlD
Erlotinib—ULK3—nervous system—multiple sclerosis	0.000763	0.0113	CbGeAlD
Erlotinib—PIP4K2C—cerebellum—multiple sclerosis	0.000752	0.0111	CbGeAlD
Erlotinib—ABL1—retina—multiple sclerosis	0.00075	0.0111	CbGeAlD
Erlotinib—ULK3—central nervous system—multiple sclerosis	0.000735	0.0109	CbGeAlD
Erlotinib—MKNK1—nervous system—multiple sclerosis	0.000718	0.0106	CbGeAlD
Erlotinib—ULK3—cerebellum—multiple sclerosis	0.000718	0.0106	CbGeAlD
Erlotinib—MAP2K5—medulla oblongata—multiple sclerosis	0.000703	0.0104	CbGeAlD
Erlotinib—MKNK1—central nervous system—multiple sclerosis	0.000692	0.0102	CbGeAlD
Erlotinib—MKNK1—cerebellum—multiple sclerosis	0.000676	0.01	CbGeAlD
Erlotinib—ABL2—brain—multiple sclerosis	0.000646	0.00957	CbGeAlD
Erlotinib—MAP2K5—midbrain—multiple sclerosis	0.000643	0.00952	CbGeAlD
Erlotinib—SLK—cerebellum—multiple sclerosis	0.00064	0.00949	CbGeAlD
Erlotinib—EGFR—brain—multiple sclerosis	0.00063	0.00934	CbGeAlD
Erlotinib—MAP2K5—spinal cord—multiple sclerosis	0.000627	0.00929	CbGeAlD
Erlotinib—PIP4K2C—brain—multiple sclerosis	0.000611	0.00905	CbGeAlD
Erlotinib—STK10—nervous system—multiple sclerosis	0.000591	0.00877	CbGeAlD
Erlotinib—ULK3—brain—multiple sclerosis	0.000583	0.00865	CbGeAlD
Erlotinib—STK10—central nervous system—multiple sclerosis	0.000569	0.00844	CbGeAlD
Erlotinib—STK10—cerebellum—multiple sclerosis	0.000557	0.00825	CbGeAlD
Erlotinib—MKNK1—brain—multiple sclerosis	0.000549	0.00814	CbGeAlD
Erlotinib—SLCO2B1—medulla oblongata—multiple sclerosis	0.000547	0.00811	CbGeAlD
Erlotinib—ABL1—medulla oblongata—multiple sclerosis	0.000542	0.00804	CbGeAlD
Erlotinib—MAP2K5—nervous system—multiple sclerosis	0.000528	0.00783	CbGeAlD
Erlotinib—SLK—brain—multiple sclerosis	0.00052	0.00771	CbGeAlD
Erlotinib—ORM1—spinal cord—multiple sclerosis	0.000509	0.00754	CbGeAlD
Erlotinib—MAP2K5—central nervous system—multiple sclerosis	0.000509	0.00754	CbGeAlD
Erlotinib—MAP2K5—cerebellum—multiple sclerosis	0.000497	0.00737	CbGeAlD
Erlotinib—ABL1—midbrain—multiple sclerosis	0.000496	0.00735	CbGeAlD
Erlotinib—SLCO2B1—spinal cord—multiple sclerosis	0.000488	0.00723	CbGeAlD
Erlotinib—ABL1—spinal cord—multiple sclerosis	0.000484	0.00717	CbGeAlD
Erlotinib—STK10—brain—multiple sclerosis	0.000452	0.0067	CbGeAlD
Erlotinib—ORM1—nervous system—multiple sclerosis	0.000429	0.00636	CbGeAlD
Erlotinib—ORM1—central nervous system—multiple sclerosis	0.000413	0.00612	CbGeAlD
Erlotinib—SLCO2B1—nervous system—multiple sclerosis	0.000411	0.00609	CbGeAlD
Erlotinib—ABL1—nervous system—multiple sclerosis	0.000407	0.00604	CbGeAlD
Erlotinib—MAP2K5—brain—multiple sclerosis	0.000404	0.00598	CbGeAlD
Erlotinib—SLCO2B1—central nervous system—multiple sclerosis	0.000396	0.00586	CbGeAlD
Erlotinib—ABL1—central nervous system—multiple sclerosis	0.000392	0.00581	CbGeAlD
Erlotinib—SLCO2B1—cerebellum—multiple sclerosis	0.000387	0.00573	CbGeAlD
Erlotinib—ABL1—cerebellum—multiple sclerosis	0.000383	0.00568	CbGeAlD
Erlotinib—CYP1B1—nervous system—multiple sclerosis	0.000345	0.00511	CbGeAlD
Erlotinib—ABCG2—medulla oblongata—multiple sclerosis	0.000342	0.00507	CbGeAlD
Erlotinib—CYP2D6—brainstem—multiple sclerosis	0.000336	0.00498	CbGeAlD
Erlotinib—CYP1B1—central nervous system—multiple sclerosis	0.000332	0.00492	CbGeAlD
Erlotinib—CYP1B1—cerebellum—multiple sclerosis	0.000325	0.00481	CbGeAlD
Erlotinib—SLCO2B1—brain—multiple sclerosis	0.000314	0.00466	CbGeAlD
Erlotinib—ABCG2—midbrain—multiple sclerosis	0.000313	0.00463	CbGeAlD
Erlotinib—ABL1—brain—multiple sclerosis	0.000311	0.00462	CbGeAlD
Erlotinib—ABCG2—spinal cord—multiple sclerosis	0.000305	0.00452	CbGeAlD
Erlotinib—ALB—brain—multiple sclerosis	0.000287	0.00426	CbGeAlD
Erlotinib—CYP1B1—brain—multiple sclerosis	0.000264	0.00391	CbGeAlD
Erlotinib—CYP1A1—nervous system—multiple sclerosis	0.000244	0.00362	CbGeAlD
Erlotinib—ABCG2—cerebellum—multiple sclerosis	0.000242	0.00358	CbGeAlD
Erlotinib—CYP1A1—central nervous system—multiple sclerosis	0.000235	0.00348	CbGeAlD
Erlotinib—ABCB1—retina—multiple sclerosis	0.000233	0.00346	CbGeAlD
Erlotinib—CYP2C8—brain—multiple sclerosis	0.000202	0.00299	CbGeAlD
Erlotinib—ABCG2—brain—multiple sclerosis	0.000196	0.00291	CbGeAlD
Erlotinib—CYP1A1—brain—multiple sclerosis	0.000186	0.00276	CbGeAlD
Erlotinib—CYP3A4—nervous system—multiple sclerosis	0.000179	0.00265	CbGeAlD
Erlotinib—CYP2D6—nervous system—multiple sclerosis	0.000176	0.00261	CbGeAlD
Erlotinib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000175	0.000947	CcSEcCtD
Erlotinib—Acute coronary syndrome—Prednisone—multiple sclerosis	0.000174	0.000946	CcSEcCtD
Erlotinib—Myocardial infarction—Prednisone—multiple sclerosis	0.000174	0.000941	CcSEcCtD
Erlotinib—Neuropathy peripheral—Prednisone—multiple sclerosis	0.000174	0.000941	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	0.000173	0.000937	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000173	0.000936	CcSEcCtD
Erlotinib—CYP3A4—central nervous system—multiple sclerosis	0.000172	0.00255	CbGeAlD
Erlotinib—Nausea—Cladribine—multiple sclerosis	0.000171	0.000928	CcSEcCtD
Erlotinib—Syncope—Prednisolone—multiple sclerosis	0.000171	0.000926	CcSEcCtD
Erlotinib—Eye disorder—Dexamethasone—multiple sclerosis	0.000171	0.000925	CcSEcCtD
Erlotinib—Eye disorder—Betamethasone—multiple sclerosis	0.000171	0.000925	CcSEcCtD
Erlotinib—CYP2D6—central nervous system—multiple sclerosis	0.00017	0.00251	CbGeAlD
Erlotinib—Back pain—Triamcinolone—multiple sclerosis	0.000169	0.000918	CcSEcCtD
Erlotinib—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000169	0.000915	CcSEcCtD
Erlotinib—ABCB1—medulla oblongata—multiple sclerosis	0.000169	0.0025	CbGeAlD
Erlotinib—Loss of consciousness—Prednisolone—multiple sclerosis	0.000167	0.000907	CcSEcCtD
Erlotinib—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000167	0.000904	CcSEcCtD
Erlotinib—CYP2D6—cerebellum—multiple sclerosis	0.000166	0.00246	CbGeAlD
Erlotinib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000165	0.000893	CcSEcCtD
Erlotinib—Fatigue—Mitoxantrone—multiple sclerosis	0.000163	0.000885	CcSEcCtD
Erlotinib—Arrhythmia—Betamethasone—multiple sclerosis	0.000163	0.000884	CcSEcCtD
Erlotinib—Arrhythmia—Dexamethasone—multiple sclerosis	0.000163	0.000884	CcSEcCtD
Erlotinib—Pancreatitis—Methotrexate—multiple sclerosis	0.000163	0.000882	CcSEcCtD
Erlotinib—Pain—Mitoxantrone—multiple sclerosis	0.000162	0.000878	CcSEcCtD
Erlotinib—Constipation—Mitoxantrone—multiple sclerosis	0.000162	0.000878	CcSEcCtD
Erlotinib—Alopecia—Betamethasone—multiple sclerosis	0.000161	0.000874	CcSEcCtD
Erlotinib—Alopecia—Dexamethasone—multiple sclerosis	0.000161	0.000874	CcSEcCtD
Erlotinib—Diarrhoea—Azathioprine—multiple sclerosis	0.00016	0.000869	CcSEcCtD
Erlotinib—Haemoglobin—Prednisone—multiple sclerosis	0.00016	0.000866	CcSEcCtD
Erlotinib—Haemorrhage—Prednisone—multiple sclerosis	0.000159	0.000862	CcSEcCtD
Erlotinib—Erythema—Betamethasone—multiple sclerosis	0.000159	0.000861	CcSEcCtD
Erlotinib—Erythema—Dexamethasone—multiple sclerosis	0.000159	0.000861	CcSEcCtD
Erlotinib—Syncope—Triamcinolone—multiple sclerosis	0.000157	0.000851	CcSEcCtD
Erlotinib—Syncope—Methylprednisolone—multiple sclerosis	0.000157	0.000849	CcSEcCtD
Erlotinib—Connective tissue disorder—Prednisone—multiple sclerosis	0.000156	0.000847	CcSEcCtD
Erlotinib—Oedema—Prednisolone—multiple sclerosis	0.000155	0.000842	CcSEcCtD
Erlotinib—Neutropenia—Methotrexate—multiple sclerosis	0.000155	0.000841	CcSEcCtD
Erlotinib—Dizziness—Azathioprine—multiple sclerosis	0.000155	0.00084	CcSEcCtD
Erlotinib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000155	0.00084	CcSEcCtD
Erlotinib—ABCB1—midbrain—multiple sclerosis	0.000154	0.00228	CbGeAlD
Erlotinib—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000154	0.000834	CcSEcCtD
Erlotinib—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000154	0.000832	CcSEcCtD
Erlotinib—Shock—Prednisolone—multiple sclerosis	0.000153	0.000829	CcSEcCtD
Erlotinib—Cough—Triamcinolone—multiple sclerosis	0.000153	0.000828	CcSEcCtD
Erlotinib—ABCB1—spinal cord—multiple sclerosis	0.00015	0.00223	CbGeAlD
Erlotinib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.00015	0.000812	CcSEcCtD
Erlotinib—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00015	0.000812	CcSEcCtD
Erlotinib—Myalgia—Triamcinolone—multiple sclerosis	0.000149	0.000808	CcSEcCtD
Erlotinib—Vomiting—Azathioprine—multiple sclerosis	0.000149	0.000808	CcSEcCtD
Erlotinib—Pneumonia—Methotrexate—multiple sclerosis	0.000149	0.000807	CcSEcCtD
Erlotinib—Arthralgia—Methylprednisolone—multiple sclerosis	0.000149	0.000806	CcSEcCtD
Erlotinib—Myalgia—Methylprednisolone—multiple sclerosis	0.000149	0.000806	CcSEcCtD
Erlotinib—Eye disorder—Prednisone—multiple sclerosis	0.000148	0.000805	CcSEcCtD
Erlotinib—Anxiety—Methylprednisolone—multiple sclerosis	0.000148	0.000804	CcSEcCtD
Erlotinib—Infestation NOS—Methotrexate—multiple sclerosis	0.000148	0.000802	CcSEcCtD
Erlotinib—Infestation—Methotrexate—multiple sclerosis	0.000148	0.000802	CcSEcCtD
Erlotinib—Rash—Azathioprine—multiple sclerosis	0.000148	0.000801	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000148	0.000801	CcSEcCtD
Erlotinib—Dermatitis—Azathioprine—multiple sclerosis	0.000148	0.0008	CcSEcCtD
Erlotinib—Depression—Methotrexate—multiple sclerosis	0.000148	0.0008	CcSEcCtD
Erlotinib—Headache—Azathioprine—multiple sclerosis	0.000147	0.000796	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000147	0.000795	CcSEcCtD
Erlotinib—Renal failure—Methotrexate—multiple sclerosis	0.000145	0.000789	CcSEcCtD
Erlotinib—Stomatitis—Methotrexate—multiple sclerosis	0.000144	0.000782	CcSEcCtD
Erlotinib—Conjunctivitis—Methotrexate—multiple sclerosis	0.000144	0.00078	CcSEcCtD
Erlotinib—Oedema—Triamcinolone—multiple sclerosis	0.000143	0.000775	CcSEcCtD
Erlotinib—Syncope—Betamethasone—multiple sclerosis	0.000142	0.000772	CcSEcCtD
Erlotinib—Syncope—Dexamethasone—multiple sclerosis	0.000142	0.000772	CcSEcCtD
Erlotinib—Arrhythmia—Prednisone—multiple sclerosis	0.000142	0.00077	CcSEcCtD
Erlotinib—Infection—Triamcinolone—multiple sclerosis	0.000142	0.00077	CcSEcCtD
Erlotinib—Infection—Methylprednisolone—multiple sclerosis	0.000142	0.000768	CcSEcCtD
Erlotinib—Shock—Triamcinolone—multiple sclerosis	0.000141	0.000762	CcSEcCtD
Erlotinib—Insomnia—Prednisolone—multiple sclerosis	0.000141	0.000762	CcSEcCtD
Erlotinib—Alopecia—Prednisone—multiple sclerosis	0.00014	0.000761	CcSEcCtD
Erlotinib—Shock—Methylprednisolone—multiple sclerosis	0.00014	0.00076	CcSEcCtD
Erlotinib—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.00014	0.000759	CcSEcCtD
Erlotinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00014	0.000758	CcSEcCtD
Erlotinib—Loss of consciousness—Dexamethasone—multiple sclerosis	0.00014	0.000757	CcSEcCtD
Erlotinib—Loss of consciousness—Betamethasone—multiple sclerosis	0.00014	0.000757	CcSEcCtD
Erlotinib—Epistaxis—Methotrexate—multiple sclerosis	0.00014	0.000757	CcSEcCtD
Erlotinib—Mental disorder—Prednisone—multiple sclerosis	0.000139	0.000755	CcSEcCtD
Erlotinib—Nausea—Azathioprine—multiple sclerosis	0.000139	0.000754	CcSEcCtD
Erlotinib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000138	0.000751	CcSEcCtD
Erlotinib—Erythema—Prednisone—multiple sclerosis	0.000138	0.00075	CcSEcCtD
Erlotinib—Malnutrition—Prednisone—multiple sclerosis	0.000138	0.00075	CcSEcCtD
Erlotinib—Vandetanib—ALB—multiple sclerosis	0.000137	0.513	CrCbGaD
Erlotinib—Asthenia—Mitoxantrone—multiple sclerosis	0.000136	0.000737	CcSEcCtD
Erlotinib—Myalgia—Betamethasone—multiple sclerosis	0.000135	0.000733	CcSEcCtD
Erlotinib—Myalgia—Dexamethasone—multiple sclerosis	0.000135	0.000733	CcSEcCtD
Erlotinib—Anxiety—Betamethasone—multiple sclerosis	0.000135	0.000731	CcSEcCtD
Erlotinib—Anxiety—Dexamethasone—multiple sclerosis	0.000135	0.000731	CcSEcCtD
Erlotinib—CYP2D6—brain—multiple sclerosis	0.000135	0.002	CbGeAlD
Erlotinib—Haemoglobin—Methotrexate—multiple sclerosis	0.000133	0.000724	CcSEcCtD
Erlotinib—Pain—Prednisolone—multiple sclerosis	0.000133	0.00072	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—multiple sclerosis	0.000133	0.00072	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—multiple sclerosis	0.000133	0.00072	CcSEcCtD
Erlotinib—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000131	0.000711	CcSEcCtD
Erlotinib—Urethral disorder—Methotrexate—multiple sclerosis	0.00013	0.000706	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00013	0.000706	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00013	0.000704	CcSEcCtD
Erlotinib—Gefitinib—ALB—multiple sclerosis	0.00013	0.487	CrCbGaD
Erlotinib—Oedema—Dexamethasone—multiple sclerosis	0.00013	0.000703	CcSEcCtD
Erlotinib—Oedema—Betamethasone—multiple sclerosis	0.00013	0.000703	CcSEcCtD
Erlotinib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00013	0.000703	CcSEcCtD
Erlotinib—Insomnia—Triamcinolone—multiple sclerosis	0.000129	0.000701	CcSEcCtD
Erlotinib—Insomnia—Methylprednisolone—multiple sclerosis	0.000129	0.000699	CcSEcCtD
Erlotinib—Infection—Dexamethasone—multiple sclerosis	0.000129	0.000698	CcSEcCtD
Erlotinib—Infection—Betamethasone—multiple sclerosis	0.000129	0.000698	CcSEcCtD
Erlotinib—Shock—Dexamethasone—multiple sclerosis	0.000128	0.000692	CcSEcCtD
Erlotinib—Shock—Betamethasone—multiple sclerosis	0.000128	0.000692	CcSEcCtD
Erlotinib—Dyspnoea—Triamcinolone—multiple sclerosis	0.000127	0.000691	CcSEcCtD
Erlotinib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000127	0.000689	CcSEcCtD
Erlotinib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000127	0.000689	CcSEcCtD
Erlotinib—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000127	0.000688	CcSEcCtD
Erlotinib—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000127	0.000688	CcSEcCtD
Erlotinib—ABCB1—nervous system—multiple sclerosis	0.000127	0.00188	CbGeAlD
Erlotinib—Dyspepsia—Triamcinolone—multiple sclerosis	0.000126	0.000682	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—multiple sclerosis	0.000126	0.000681	CcSEcCtD
Erlotinib—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000125	0.00068	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—multiple sclerosis	0.000124	0.000673	CcSEcCtD
Erlotinib—Syncope—Prednisone—multiple sclerosis	0.000124	0.000673	CcSEcCtD
Erlotinib—Anorexia—Betamethasone—multiple sclerosis	0.000124	0.00067	CcSEcCtD
Erlotinib—Anorexia—Dexamethasone—multiple sclerosis	0.000124	0.00067	CcSEcCtD
Erlotinib—Fatigue—Triamcinolone—multiple sclerosis	0.000123	0.000668	CcSEcCtD
Erlotinib—Fatigue—Methylprednisolone—multiple sclerosis	0.000123	0.000666	CcSEcCtD
Erlotinib—Pain—Triamcinolone—multiple sclerosis	0.000122	0.000662	CcSEcCtD
Erlotinib—ABCB1—central nervous system—multiple sclerosis	0.000122	0.00181	CbGeAlD
Erlotinib—Loss of consciousness—Prednisone—multiple sclerosis	0.000122	0.000659	CcSEcCtD
Erlotinib—Vomiting—Mitoxantrone—multiple sclerosis	0.00012	0.000653	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00012	0.000649	CcSEcCtD
Erlotinib—Rash—Mitoxantrone—multiple sclerosis	0.000119	0.000647	CcSEcCtD
Erlotinib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000119	0.000647	CcSEcCtD
Erlotinib—ABCB1—cerebellum—multiple sclerosis	0.000119	0.00177	CbGeAlD
Erlotinib—Chills—Methotrexate—multiple sclerosis	0.000119	0.000646	CcSEcCtD
Erlotinib—Headache—Mitoxantrone—multiple sclerosis	0.000119	0.000643	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000118	0.00064	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000118	0.00064	CcSEcCtD
Erlotinib—Myalgia—Prednisone—multiple sclerosis	0.000118	0.000639	CcSEcCtD
Erlotinib—Arthralgia—Prednisone—multiple sclerosis	0.000118	0.000639	CcSEcCtD
Erlotinib—Anxiety—Prednisone—multiple sclerosis	0.000117	0.000636	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—multiple sclerosis	0.000117	0.000636	CcSEcCtD
Erlotinib—Insomnia—Dexamethasone—multiple sclerosis	0.000117	0.000636	CcSEcCtD
Erlotinib—Insomnia—Betamethasone—multiple sclerosis	0.000117	0.000636	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000117	0.000634	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000117	0.000632	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—multiple sclerosis	0.000116	0.000631	CcSEcCtD
Erlotinib—Erythema—Methotrexate—multiple sclerosis	0.000116	0.000627	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—multiple sclerosis	0.000116	0.000627	CcSEcCtD
Erlotinib—Dyspepsia—Dexamethasone—multiple sclerosis	0.000114	0.000619	CcSEcCtD
Erlotinib—Dyspepsia—Betamethasone—multiple sclerosis	0.000114	0.000619	CcSEcCtD
Erlotinib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000113	0.000612	CcSEcCtD
Erlotinib—Oedema—Prednisone—multiple sclerosis	0.000113	0.000612	CcSEcCtD
Erlotinib—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000113	0.000611	CcSEcCtD
Erlotinib—Decreased appetite—Betamethasone—multiple sclerosis	0.000113	0.000611	CcSEcCtD
Erlotinib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000113	0.000611	CcSEcCtD
Erlotinib—Nausea—Mitoxantrone—multiple sclerosis	0.000112	0.00061	CcSEcCtD
Erlotinib—Infection—Prednisone—multiple sclerosis	0.000112	0.000608	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000112	0.000607	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000112	0.000607	CcSEcCtD
Erlotinib—Back pain—Methotrexate—multiple sclerosis	0.000112	0.000606	CcSEcCtD
Erlotinib—Fatigue—Dexamethasone—multiple sclerosis	0.000112	0.000606	CcSEcCtD
Erlotinib—Fatigue—Betamethasone—multiple sclerosis	0.000112	0.000606	CcSEcCtD
Erlotinib—Shock—Prednisone—multiple sclerosis	0.000111	0.000602	CcSEcCtD
Erlotinib—Pain—Betamethasone—multiple sclerosis	0.000111	0.000601	CcSEcCtD
Erlotinib—Pain—Dexamethasone—multiple sclerosis	0.000111	0.000601	CcSEcCtD
Erlotinib—Nervous system disorder—Prednisone—multiple sclerosis	0.000111	0.0006	CcSEcCtD
Erlotinib—Skin disorder—Prednisone—multiple sclerosis	0.00011	0.000595	CcSEcCtD
Erlotinib—Anorexia—Prednisone—multiple sclerosis	0.000108	0.000584	CcSEcCtD
Erlotinib—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000106	0.000575	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000106	0.000575	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000103	0.000558	CcSEcCtD
Erlotinib—Dizziness—Prednisolone—multiple sclerosis	0.000103	0.000557	CcSEcCtD
Erlotinib—Asthenia—Triamcinolone—multiple sclerosis	0.000103	0.000556	CcSEcCtD
Erlotinib—Body temperature increased—Dexamethasone—multiple sclerosis	0.000102	0.000556	CcSEcCtD
Erlotinib—Body temperature increased—Betamethasone—multiple sclerosis	0.000102	0.000556	CcSEcCtD
Erlotinib—Abdominal pain—Betamethasone—multiple sclerosis	0.000102	0.000556	CcSEcCtD
Erlotinib—Abdominal pain—Dexamethasone—multiple sclerosis	0.000102	0.000556	CcSEcCtD
Erlotinib—Asthenia—Methylprednisolone—multiple sclerosis	0.000102	0.000555	CcSEcCtD
Erlotinib—Insomnia—Prednisone—multiple sclerosis	0.000102	0.000554	CcSEcCtD
Erlotinib—Pruritus—Triamcinolone—multiple sclerosis	0.000101	0.000548	CcSEcCtD
Erlotinib—Cough—Methotrexate—multiple sclerosis	0.000101	0.000547	CcSEcCtD
Erlotinib—Pruritus—Methylprednisolone—multiple sclerosis	0.000101	0.000547	CcSEcCtD
Erlotinib—Dyspepsia—Prednisone—multiple sclerosis	9.94e-05	0.000539	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—multiple sclerosis	9.84e-05	0.000534	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—multiple sclerosis	9.84e-05	0.000534	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—multiple sclerosis	9.84e-05	0.000534	CcSEcCtD
Erlotinib—Decreased appetite—Prednisone—multiple sclerosis	9.81e-05	0.000532	CcSEcCtD
Erlotinib—Rash—Prednisolone—multiple sclerosis	9.8e-05	0.000531	CcSEcCtD
Erlotinib—Dermatitis—Prednisolone—multiple sclerosis	9.79e-05	0.000531	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	9.77e-05	0.00053	CcSEcCtD
Erlotinib—Diarrhoea—Methylprednisolone—multiple sclerosis	9.75e-05	0.000529	CcSEcCtD
Erlotinib—Fatigue—Prednisone—multiple sclerosis	9.73e-05	0.000528	CcSEcCtD
Erlotinib—Headache—Prednisolone—multiple sclerosis	9.73e-05	0.000528	CcSEcCtD
Erlotinib—ABCB1—brain—multiple sclerosis	9.69e-05	0.00144	CbGeAlD
Erlotinib—Constipation—Prednisone—multiple sclerosis	9.65e-05	0.000523	CcSEcCtD
Erlotinib—Dizziness—Triamcinolone—multiple sclerosis	9.45e-05	0.000512	CcSEcCtD
Erlotinib—Dizziness—Methylprednisolone—multiple sclerosis	9.43e-05	0.000511	CcSEcCtD
Erlotinib—Infection—Methotrexate—multiple sclerosis	9.37e-05	0.000508	CcSEcCtD
Erlotinib—Asthenia—Dexamethasone—multiple sclerosis	9.3e-05	0.000504	CcSEcCtD
Erlotinib—Asthenia—Betamethasone—multiple sclerosis	9.3e-05	0.000504	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—multiple sclerosis	9.25e-05	0.000502	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—multiple sclerosis	9.24e-05	0.000501	CcSEcCtD
Erlotinib—Gastrointestinal pain—Prednisone—multiple sclerosis	9.23e-05	0.000501	CcSEcCtD
Erlotinib—Nausea—Prednisolone—multiple sclerosis	9.23e-05	0.0005	CcSEcCtD
Erlotinib—Pruritus—Betamethasone—multiple sclerosis	9.17e-05	0.000497	CcSEcCtD
Erlotinib—Pruritus—Dexamethasone—multiple sclerosis	9.17e-05	0.000497	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—multiple sclerosis	9.16e-05	0.000497	CcSEcCtD
Erlotinib—Vomiting—Triamcinolone—multiple sclerosis	9.08e-05	0.000493	CcSEcCtD
Erlotinib—Vomiting—Methylprednisolone—multiple sclerosis	9.06e-05	0.000491	CcSEcCtD
Erlotinib—Rash—Triamcinolone—multiple sclerosis	9.01e-05	0.000488	CcSEcCtD
Erlotinib—Dermatitis—Triamcinolone—multiple sclerosis	9e-05	0.000488	CcSEcCtD
Erlotinib—Anorexia—Methotrexate—multiple sclerosis	8.99e-05	0.000488	CcSEcCtD
Erlotinib—Rash—Methylprednisolone—multiple sclerosis	8.99e-05	0.000487	CcSEcCtD
Erlotinib—Dermatitis—Methylprednisolone—multiple sclerosis	8.98e-05	0.000487	CcSEcCtD
Erlotinib—Headache—Triamcinolone—multiple sclerosis	8.95e-05	0.000485	CcSEcCtD
Erlotinib—Headache—Methylprednisolone—multiple sclerosis	8.93e-05	0.000484	CcSEcCtD
Erlotinib—Abdominal pain—Prednisone—multiple sclerosis	8.92e-05	0.000484	CcSEcCtD
Erlotinib—Body temperature increased—Prednisone—multiple sclerosis	8.92e-05	0.000484	CcSEcCtD
Erlotinib—Diarrhoea—Dexamethasone—multiple sclerosis	8.87e-05	0.000481	CcSEcCtD
Erlotinib—Diarrhoea—Betamethasone—multiple sclerosis	8.87e-05	0.000481	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	8.6e-05	0.000466	CcSEcCtD
Erlotinib—Dizziness—Dexamethasone—multiple sclerosis	8.57e-05	0.000465	CcSEcCtD
Erlotinib—Dizziness—Betamethasone—multiple sclerosis	8.57e-05	0.000465	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—multiple sclerosis	8.53e-05	0.000463	CcSEcCtD
Erlotinib—Nausea—Triamcinolone—multiple sclerosis	8.49e-05	0.00046	CcSEcCtD
Erlotinib—Nausea—Methylprednisolone—multiple sclerosis	8.47e-05	0.000459	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—multiple sclerosis	8.41e-05	0.000456	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—multiple sclerosis	8.3e-05	0.00045	CcSEcCtD
Erlotinib—Vomiting—Dexamethasone—multiple sclerosis	8.24e-05	0.000447	CcSEcCtD
Erlotinib—Vomiting—Betamethasone—multiple sclerosis	8.24e-05	0.000447	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—multiple sclerosis	8.2e-05	0.000445	CcSEcCtD
Erlotinib—Rash—Dexamethasone—multiple sclerosis	8.17e-05	0.000443	CcSEcCtD
Erlotinib—Rash—Betamethasone—multiple sclerosis	8.17e-05	0.000443	CcSEcCtD
Erlotinib—Dermatitis—Dexamethasone—multiple sclerosis	8.17e-05	0.000443	CcSEcCtD
Erlotinib—Dermatitis—Betamethasone—multiple sclerosis	8.17e-05	0.000443	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	8.15e-05	0.000442	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—multiple sclerosis	8.13e-05	0.000441	CcSEcCtD
Erlotinib—Headache—Betamethasone—multiple sclerosis	8.12e-05	0.00044	CcSEcCtD
Erlotinib—Headache—Dexamethasone—multiple sclerosis	8.12e-05	0.00044	CcSEcCtD
Erlotinib—Asthenia—Prednisone—multiple sclerosis	8.1e-05	0.000439	CcSEcCtD
Erlotinib—Pain—Methotrexate—multiple sclerosis	8.07e-05	0.000437	CcSEcCtD
Erlotinib—Pruritus—Prednisone—multiple sclerosis	7.99e-05	0.000433	CcSEcCtD
Erlotinib—Diarrhoea—Prednisone—multiple sclerosis	7.72e-05	0.000419	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—multiple sclerosis	7.71e-05	0.000418	CcSEcCtD
Erlotinib—Nausea—Dexamethasone—multiple sclerosis	7.7e-05	0.000418	CcSEcCtD
Erlotinib—Nausea—Betamethasone—multiple sclerosis	7.7e-05	0.000418	CcSEcCtD
Erlotinib—Dizziness—Prednisone—multiple sclerosis	7.47e-05	0.000405	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—multiple sclerosis	7.46e-05	0.000404	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—multiple sclerosis	7.46e-05	0.000404	CcSEcCtD
Erlotinib—Vomiting—Prednisone—multiple sclerosis	7.18e-05	0.000389	CcSEcCtD
Erlotinib—Rash—Prednisone—multiple sclerosis	7.12e-05	0.000386	CcSEcCtD
Erlotinib—Dermatitis—Prednisone—multiple sclerosis	7.11e-05	0.000386	CcSEcCtD
Erlotinib—Headache—Prednisone—multiple sclerosis	7.07e-05	0.000383	CcSEcCtD
Erlotinib—Asthenia—Methotrexate—multiple sclerosis	6.77e-05	0.000367	CcSEcCtD
Erlotinib—Nausea—Prednisone—multiple sclerosis	6.71e-05	0.000364	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—multiple sclerosis	6.67e-05	0.000362	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—multiple sclerosis	6.46e-05	0.00035	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—multiple sclerosis	6.24e-05	0.000338	CcSEcCtD
Erlotinib—Vomiting—Methotrexate—multiple sclerosis	6e-05	0.000325	CcSEcCtD
Erlotinib—Rash—Methotrexate—multiple sclerosis	5.95e-05	0.000323	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—multiple sclerosis	5.94e-05	0.000322	CcSEcCtD
Erlotinib—Headache—Methotrexate—multiple sclerosis	5.91e-05	0.00032	CcSEcCtD
Erlotinib—Nausea—Methotrexate—multiple sclerosis	5.6e-05	0.000304	CcSEcCtD
Erlotinib—JAK3—Signaling Pathways—APOE—multiple sclerosis	1.47e-05	0.000116	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCL5—multiple sclerosis	1.46e-05	0.000115	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—MAPK1—multiple sclerosis	1.46e-05	0.000115	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	1.45e-05	0.000115	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL1B—multiple sclerosis	1.45e-05	0.000114	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL2—multiple sclerosis	1.45e-05	0.000114	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD86—multiple sclerosis	1.44e-05	0.000114	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD40LG—multiple sclerosis	1.42e-05	0.000112	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—IL2—multiple sclerosis	1.41e-05	0.000111	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—RRM1—multiple sclerosis	1.41e-05	0.000111	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—BCHE—multiple sclerosis	1.41e-05	0.000111	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.41e-05	0.000111	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD8A—multiple sclerosis	1.4e-05	0.00011	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.4e-05	0.00011	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.4e-05	0.00011	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.39e-05	0.00011	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MYC—multiple sclerosis	1.38e-05	0.000109	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CD4—multiple sclerosis	1.38e-05	0.000109	CbGpPWpGaD
Erlotinib—MKNK1—Disease—TGFB1—multiple sclerosis	1.38e-05	0.000109	CbGpPWpGaD
Erlotinib—EGFR—Immune System—VCAM1—multiple sclerosis	1.37e-05	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-DQA1—multiple sclerosis	1.37e-05	0.000108	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP9—multiple sclerosis	1.36e-05	0.000107	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GPC5—multiple sclerosis	1.36e-05	0.000107	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SPP1—multiple sclerosis	1.36e-05	0.000107	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MAPK1—multiple sclerosis	1.35e-05	0.000107	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	1.35e-05	0.000106	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-B—multiple sclerosis	1.35e-05	0.000106	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CD80—multiple sclerosis	1.33e-05	0.000105	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCL5—multiple sclerosis	1.33e-05	0.000105	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—MYC—multiple sclerosis	1.32e-05	0.000104	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCR5—multiple sclerosis	1.32e-05	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MAPK1—multiple sclerosis	1.32e-05	0.000104	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—BCHE—multiple sclerosis	1.31e-05	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—TYK2—multiple sclerosis	1.3e-05	0.000103	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2RA—multiple sclerosis	1.3e-05	0.000103	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SRM—multiple sclerosis	1.3e-05	0.000102	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—RRM1—multiple sclerosis	1.29e-05	0.000102	CbGpPWpGaD
Erlotinib—ALB—Metabolism—RRM1—multiple sclerosis	1.28e-05	0.000101	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-DQB1—multiple sclerosis	1.28e-05	0.000101	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.28e-05	0.000101	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—POMC—multiple sclerosis	1.26e-05	9.97e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2RA—multiple sclerosis	1.26e-05	9.96e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-A—multiple sclerosis	1.25e-05	9.85e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL2—multiple sclerosis	1.24e-05	9.78e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCL2—multiple sclerosis	1.24e-05	9.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD86—multiple sclerosis	1.23e-05	9.74e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—STAT3—multiple sclerosis	1.22e-05	9.6e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL3—multiple sclerosis	1.21e-05	9.58e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—STAT3—multiple sclerosis	1.21e-05	9.55e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—MAPK1—multiple sclerosis	1.21e-05	9.55e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD40LG—multiple sclerosis	1.21e-05	9.55e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.2e-05	9.49e-05	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.2e-05	9.48e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—APOE—multiple sclerosis	1.2e-05	9.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCR5—multiple sclerosis	1.2e-05	9.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD8A—multiple sclerosis	1.2e-05	9.44e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—BCHE—multiple sclerosis	1.19e-05	9.43e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2RA—multiple sclerosis	1.18e-05	9.35e-05	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—IL6—multiple sclerosis	1.18e-05	9.35e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.18e-05	9.35e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.18e-05	9.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2RA—multiple sclerosis	1.18e-05	9.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CD4—multiple sclerosis	1.18e-05	9.31e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MMP9—multiple sclerosis	1.17e-05	9.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTGER4—multiple sclerosis	1.17e-05	9.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP9—multiple sclerosis	1.16e-05	9.18e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.16e-05	9.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-B—multiple sclerosis	1.15e-05	9.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PGR—multiple sclerosis	1.15e-05	9.08e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—TLR4—multiple sclerosis	1.14e-05	9.01e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-DRB1—multiple sclerosis	1.14e-05	9e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD86—multiple sclerosis	1.14e-05	8.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD4—multiple sclerosis	1.13e-05	8.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCR3—multiple sclerosis	1.13e-05	8.91e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—RRM1—multiple sclerosis	1.12e-05	8.87e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TYK2—multiple sclerosis	1.12e-05	8.86e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TGFB1—multiple sclerosis	1.12e-05	8.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—IL6—multiple sclerosis	1.12e-05	8.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CD28—multiple sclerosis	1.12e-05	8.82e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—MAPK1—multiple sclerosis	1.11e-05	8.72e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TGFB1—multiple sclerosis	1.1e-05	8.69e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MAPK1—multiple sclerosis	1.1e-05	8.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCR2—multiple sclerosis	1.1e-05	8.66e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ICAM1—multiple sclerosis	1.09e-05	8.64e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.09e-05	8.62e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CD80—multiple sclerosis	1.08e-05	8.56e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.08e-05	8.55e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—MAPK1—multiple sclerosis	1.08e-05	8.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2RA—multiple sclerosis	1.08e-05	8.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-A—multiple sclerosis	1.07e-05	8.41e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.06e-05	8.36e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD80—multiple sclerosis	1.05e-05	8.31e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.05e-05	8.29e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TNF—multiple sclerosis	1.05e-05	8.27e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—STAT3—multiple sclerosis	1.04e-05	8.23e-05	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—multiple sclerosis	1.04e-05	8.21e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.04e-05	8.19e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.04e-05	8.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—STAT3—multiple sclerosis	1.03e-05	8.16e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.03e-05	8.13e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—POMC—multiple sclerosis	1.03e-05	8.13e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.02e-05	8.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CNR1—multiple sclerosis	1.01e-05	8e-05	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—multiple sclerosis	1.01e-05	7.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CCR5—multiple sclerosis	1.01e-05	7.97e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCL2—multiple sclerosis	1.01e-05	7.96e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1e-05	7.9e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.96e-06	7.86e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HLA-A—multiple sclerosis	9.85e-06	7.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—TLR4—multiple sclerosis	9.75e-06	7.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-DRB1—multiple sclerosis	9.74e-06	7.69e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MAPK1—multiple sclerosis	9.72e-06	7.67e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MYC—multiple sclerosis	9.69e-06	7.65e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TGFB1—multiple sclerosis	9.67e-06	7.63e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	9.66e-06	7.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TGFB1—multiple sclerosis	9.59e-06	7.57e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MAPK1—multiple sclerosis	9.48e-06	7.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MAPK1—multiple sclerosis	9.4e-06	7.42e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.38e-06	7.4e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—POMC—multiple sclerosis	9.36e-06	7.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ICAM1—multiple sclerosis	9.35e-06	7.38e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL2—multiple sclerosis	9.35e-06	7.37e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—multiple sclerosis	9.3e-06	7.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—APOE—multiple sclerosis	9.19e-06	7.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCL2—multiple sclerosis	9.16e-06	7.23e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TYK2—multiple sclerosis	9.16e-06	7.22e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	9.14e-06	7.21e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	9.14e-06	7.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL10—multiple sclerosis	9.12e-06	7.2e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD80—multiple sclerosis	9e-06	7.1e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—RRM1—multiple sclerosis	8.98e-06	7.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TNF—multiple sclerosis	8.95e-06	7.06e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—TYK2—multiple sclerosis	8.89e-06	7.02e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MMP9—multiple sclerosis	8.84e-06	6.98e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.6e-06	6.79e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—BCHE—multiple sclerosis	8.56e-06	6.75e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.56e-06	6.75e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.55e-06	6.75e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—multiple sclerosis	8.5e-06	6.7e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—APOE—multiple sclerosis	8.47e-06	6.68e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—multiple sclerosis	8.45e-06	6.67e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPC5—multiple sclerosis	8.36e-06	6.6e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IFNG—multiple sclerosis	8.33e-06	6.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TYK2—multiple sclerosis	8.32e-06	6.56e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD80—multiple sclerosis	8.31e-06	6.56e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MAPK1—multiple sclerosis	8.3e-06	6.55e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—BCHE—multiple sclerosis	8.09e-06	6.38e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD4—multiple sclerosis	8.04e-06	6.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CD86—multiple sclerosis	7.98e-06	6.29e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—APOE—multiple sclerosis	7.9e-06	6.23e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—STAT3—multiple sclerosis	7.86e-06	6.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL5—multiple sclerosis	7.85e-06	6.2e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.84e-06	6.19e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2—multiple sclerosis	7.62e-06	6.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—TYK2—multiple sclerosis	7.6e-06	6e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—multiple sclerosis	7.47e-06	5.89e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL1B—multiple sclerosis	7.43e-06	5.86e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—BCHE—multiple sclerosis	7.41e-06	5.85e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2—multiple sclerosis	7.4e-06	5.84e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—BCHE—multiple sclerosis	7.37e-06	5.82e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MYC—multiple sclerosis	7.31e-06	5.77e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TGFB1—multiple sclerosis	7.29e-06	5.75e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—multiple sclerosis	7.28e-06	5.75e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—POMC—multiple sclerosis	7.28e-06	5.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SPP1—multiple sclerosis	7.27e-06	5.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—multiple sclerosis	7.22e-06	5.7e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MMP9—multiple sclerosis	7.21e-06	5.69e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—APOE—multiple sclerosis	7.19e-06	5.67e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MAPK1—multiple sclerosis	7.15e-06	5.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IFNG—multiple sclerosis	7.12e-06	5.61e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCR5—multiple sclerosis	7.08e-06	5.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—TYK2—multiple sclerosis	7.02e-06	5.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2RA—multiple sclerosis	6.97e-06	5.5e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.96e-06	5.5e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—multiple sclerosis	6.95e-06	5.48e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—RRM1—multiple sclerosis	6.93e-06	5.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—multiple sclerosis	6.92e-06	5.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD4—multiple sclerosis	6.87e-06	5.42e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—POMC—multiple sclerosis	6.79e-06	5.35e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ALB—multiple sclerosis	6.63e-06	5.23e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	6.5e-06	5.13e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—BCHE—multiple sclerosis	6.46e-06	5.1e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APOE—multiple sclerosis	6.44e-06	5.08e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—multiple sclerosis	6.41e-06	5.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—multiple sclerosis	6.38e-06	5.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1B—multiple sclerosis	6.35e-06	5.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD4—multiple sclerosis	6.34e-06	5.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—multiple sclerosis	6.32e-06	4.99e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—multiple sclerosis	6.23e-06	4.91e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ALB—multiple sclerosis	6.19e-06	4.88e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—POMC—multiple sclerosis	6.17e-06	4.87e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—BCHE—multiple sclerosis	6.09e-06	4.8e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.98e-06	4.72e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—multiple sclerosis	5.96e-06	4.7e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TGFB1—multiple sclerosis	5.94e-06	4.69e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK1—multiple sclerosis	5.83e-06	4.6e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CD80—multiple sclerosis	5.82e-06	4.59e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK1—multiple sclerosis	5.66e-06	4.47e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—multiple sclerosis	5.63e-06	4.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—POMC—multiple sclerosis	5.53e-06	4.36e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—multiple sclerosis	5.49e-06	4.33e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.45e-06	4.3e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—multiple sclerosis	5.42e-06	4.28e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL2—multiple sclerosis	5.41e-06	4.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—multiple sclerosis	5.32e-06	4.2e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK1—multiple sclerosis	5.31e-06	4.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK1—multiple sclerosis	5.29e-06	4.18e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—BCHE—multiple sclerosis	5.16e-06	4.07e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOE—multiple sclerosis	5.15e-06	4.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TYK2—multiple sclerosis	4.91e-06	3.88e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—multiple sclerosis	4.91e-06	3.88e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOE—multiple sclerosis	4.86e-06	3.84e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK1—multiple sclerosis	4.84e-06	3.82e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—multiple sclerosis	4.56e-06	3.6e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—multiple sclerosis	4.55e-06	3.59e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—multiple sclerosis	4.48e-06	3.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK1—multiple sclerosis	4.47e-06	3.52e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOE—multiple sclerosis	4.46e-06	3.52e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOE—multiple sclerosis	4.43e-06	3.5e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—POMC—multiple sclerosis	4.42e-06	3.49e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—multiple sclerosis	4.35e-06	3.43e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—POMC—multiple sclerosis	4.18e-06	3.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—multiple sclerosis	4.09e-06	3.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—multiple sclerosis	4.07e-06	3.21e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—multiple sclerosis	4.03e-06	3.18e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.98e-06	3.14e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOE—multiple sclerosis	3.89e-06	3.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—multiple sclerosis	3.87e-06	3.05e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—POMC—multiple sclerosis	3.83e-06	3.02e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—multiple sclerosis	3.81e-06	3.01e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—POMC—multiple sclerosis	3.81e-06	3.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—multiple sclerosis	3.72e-06	2.93e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOE—multiple sclerosis	3.66e-06	2.89e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—multiple sclerosis	3.49e-06	2.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—multiple sclerosis	3.44e-06	2.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—multiple sclerosis	3.43e-06	2.71e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—POMC—multiple sclerosis	3.34e-06	2.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—multiple sclerosis	3.2e-06	2.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—multiple sclerosis	3.19e-06	2.52e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—POMC—multiple sclerosis	3.15e-06	2.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK1—multiple sclerosis	3.13e-06	2.47e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOE—multiple sclerosis	3.1e-06	2.45e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—multiple sclerosis	3.04e-06	2.4e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—multiple sclerosis	2.87e-06	2.26e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—POMC—multiple sclerosis	2.66e-06	2.1e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—multiple sclerosis	2.43e-06	1.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—multiple sclerosis	2.4e-06	1.9e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOE—multiple sclerosis	2.39e-06	1.89e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—POMC—multiple sclerosis	2.06e-06	1.62e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—multiple sclerosis	1.87e-06	1.48e-05	CbGpPWpGaD
